Company intelligence / Profile preview

Access Bio

Boyce, Virginia, United Statesaccessbio.net ↗

Ownership: Private
Employees: ~101
Development stage: Other

Overview

Access Bio has commercialized multiple rapid and molecular diagnostic products for infectious diseases including malaria, COVID‑19, HIV, and HPV. Its CareStart™ line of COVID‑19 tests received FDA Emergency Use Authorization for both point-of-care antigen/serology kits and laboratory PCR tests. The company’s malaria RDTs are widely used globally. No clinical trial results are reported as the company does not develop therapeutics.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic test (in vitro diagnostic)Molecular diagnosticsBiosensor technologyRapid diagnostic test
Industry: Molecular Diagnostics

Partnerships

Bill & Melinda Gates FoundationWorld Health Organization (WHO)UNICEF

Beyond the preview

Go deeper on Access Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Access Bio.

Explore the full profile